European Medicines Agency's workshop on nanomedicines
Date:
02/09/2010 to 03/09/2010
Location:
London
On 2-3 September 2010, EMA hosted the first international scientific workshop on nanomedicines. Some 200 European and international participants from 27 countries including Australia, Canada, India, Japan and the United States discussed benefits and challenges arising from the application of nanotechnologies to medicines. Participants included representatives from patients' organisations, health care professionals' organisations, academia, regulatory authorities and pharmaceutical industry.
-
List item
Summary report - Workshop on nanomedicines: 2-3 September 2010 (PDF/3.74 MB)
First published: 22/10/2010
Last updated: 22/10/2010
EMA/538503/2010 -
List item
Agenda - Workshop on nanomedicines: 2-3 September 2010 (PDF/173.17 KB)
First published: 15/03/2010
Last updated: 09/09/2010
EMA/273690/2010 -
List item
Presentation - Workshop on nanomedicines - Introduction, Patrick le Courtois, EMA (PDF/483.14 KB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Keynote lecture - Key ongoing applications in nanosciences and how they apply to pharmaceuticals, Rutledge Ellis-Behnke, MIT (PDF/38.7 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Engineering nanoparticles for biomedical applications, Mamoun Muhammed, Royal Institute of Technology, Stockholm (PDF/5.49 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Special aspects of nanomedicines: development, manufacturing and characterisation, Simon Holland, GlaxoSmithKline (PDF/1.11 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Special aspects of nanomedicines: Viewpoint from the industry, Jan Mà¶schwitzer, Abbott Healthcare Products B.V. (PDF/5.58 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Immunology and immunotoxicity of nanomedicines, Jacques Descotes, Lyon University Hospitals, France (PDF/193.45 KB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Nanotechnology - What about safety? How do we determine risk? Wim H de Jong, National Institute for Public Health and the Environment, Bilthoven (PDF/2.02 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Nanomedicines interaction with biological systems, Kenneth Dawson, University College of Dublin (PDF/5.14 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Nanomedicines on the market and in clinical development - Introduction, Eric Abadie, CHMP chair (PDF/751.58 KB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Liposomal nanomedicines and innovative formulations, Daan Crommelin, Utrecht University (PDF/1.64 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Polymer conjugates, Ruth Duncan, Cardiff University (PDF/11.72 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Nanoparticles, Rogà©rio Gaspar, University of Lisbon (PDF/4.31 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Novel and innovative nanotechnology-based delivery systems, Alexander Kabanov, University of Nebraska Medical Center (PDF/7.28 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Nanosystems in regenerative medicine, Jà¶ns Hilborn, Uppsala University (PDF/6.35 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Theranostics nanoparticles, Peter Dobson, Oxford University (PDF/2.69 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Safety specification - Identification and methodologies, Annalisa Rubino, EMA (PDF/465.75 KB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Pharmacovigilance and risk minimisation plans, Jan Petracek, PharmInvent (PDF/1.12 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Specific methodological issues and implications for risk assessment, Silvia Berkner, German Federal Environmental Agency (PDF/2.5 MB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Nanomedicines - Current initiatives in the US, Carlos Peà±a, FDA (PDF/164.16 KB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Nanomedicines - Current initiatives in Japan, Kumiko Sakai-Kato, Toru Kawanishi, National Institute of Health Sciences/MHLW (PDF/376.02 KB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Nanomedicines - Current initiatives in Canada, Duc Vu, Health Canada (PDF/372.3 KB)
First published: 09/09/2010
Last updated: 09/09/2010 -
List item
Presentation - Way forward, Marisa Papaluca, EMA (PDF/392.09 KB)
First published: 09/09/2010
Last updated: 09/09/2010